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ABSTRACT
Background: The aim of this study was to identify the predictive factors, among laboratory test data and pa-
tient background variables, of an efficient response to the anti-allergic agent suplatast tosilate in patients with
moderate to severe bronchial asthma.
Methods: The subjects were 44 patients with moderate to severe bronchial asthma on inhaled steroid therapy
who were enrolled in a phase II clinical trial of suplatast (300 and 600 mgday). Improvements in respiratory
function parameters and symptom scores during the first 4 weeks of administration of suplatast were assessed
to evaluate the response to the drug. Logistic regression analysis was used to relate the response to the inde-
pendent variables. Secondly, to test whether these results were applicable to clinical practice, we examined the
data from a phase III clinical trial of suplatast.
Results: Twenty-two patients were assessed as responders according to our criteria. The percentage of blood
eosinophil (%EOS, P = 0.015) and basophil (%BASO, P = 0.019) counts were identified as significant variables
to predict responders. When cut-off levels for %EOS and %BASO were set at 7.5 and 1.2, respectively, the
sensitivity for prediction of responders with lower %EOS and %BASO was 81.8% (1822). Furthermore, when
we applied the same cut-off levels to subjects of a phase III clinical trial of suplatast, the sensitivity of prediction
was found to be as high as 75.0% (68).
Conclusions: These results indicate that %EOS and %BASO are good candidates to predict the response to
suplatast among patients with moderate to severe bronchial asthma on inhaled steroid therapy. These predic-
tors may contribute, in combination with genomic information, to stratified medical treatment tailored to the indi-
vidual needs of patients.
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INTRODUCTION
Suplatast tosilate ( suplatast ) , a dimethylsulfonium
compound, is used in Japan as a therapeutic drug for
allergic diseases such as bronchial asthma, allergic
rhinitis, and atopic dermatitis.1,2 Suplatast has been
reported to attenuate the allergen-induced late asth-
matic response,3 airway hyperresponsiveness and in-
filtration of eosinophils and CD 4+ lymphocytes in
guinea pigs , 3,4 human IgE synthesis , 5 and antigen-
elicited peritoneal eosinophilia . 6 These effects are
considered to be mediated through selective inhibi-
tion of interleukin-4 (IL-4) and interleukin-5 (IL-5)
production by type-2 helper T cells (Th2-cells), with-
out any effects on Interferon-gamma (IFN-gamma)
production from type-1 helper T cells (Th1-cells).7
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Fig. 1 Study protocol. After an initial 2-week run-in peri-
od, the treatment group was administered suplatast (300 
mg/day or 600 mg/day) for 8 weeks. The responder was as-
sessed first at 4 weeks after the start of treatment.
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In clinical studies , suplatast has been shown to
have beneficial effects in symptomatic asthmatic pa-
tients, and to reduce the levels of markers of inflam-
mation and airway hyperresponsiveness. Tamaoki et
al. 8 evaluated the steroid-sparing effect of suplatast
relative to placebo in patients with steroid-dependent
asthma. When the steroid dose was halved, the pa-
tients in the suplatast group had less deterioration of
pulmonary function and of asthma symptoms. In a re-
cent study designed to further investigate the efficacy
and mechanism of action of suplatast ,
Sano et al.9 sought to determine the suppressive ef-
fects of suplatast on the eosinophilic inflammation of
the bronchial mucosa in patients with mild asthma.
They reported a significant decrease in the number of
infiltrating and activated eosinophils , besides im-
provement of the respiratory function parameters and
symptom scores.
In 2002, a phase II clinical study of suplatast was
conducted in patients with moderate to severe persis-
tent bronchial asthma on inhaled steroid therapy to
examine the reducing effect of a concomitantly ad-
ministered 8-week course of suplatast (300 and 600
mgday) on the dose level of inhaled steroids needed
to control the asthma.10 In that study, the dose level
of inhaled steroids could not be reduced in some pa-
tients, and these patients showed no improvement in
the respiratory function parameters despite concomi-
tant suplatast therapy. On the other hand, in other pa-
tients , improvement of the respiratory function pa-
rameters was observed by the 4th week; and the dose
level of the inhaled steroids could be reduced by the
8th week after the start of the study. These patients
were thus regarded as responders to suplatast. These
results strongly suggest that there are responders
and nonresponders to suplatast therapy.10 The data
from this clinical study were analyzed in-depth to de-
velop a method for predicting the response to
suplatast. Focusing on the routine pre-treatment labo-
ratory parameters and background variables of the
patients, we attempted to identify factors that might
be predictive of the responses of these patients to this
drug. The factors thus identified were retrospectively
analyzed among the subjects of a previously per-
formed phase III clinical study to verify their useful-
ness in predicting the response to suplatast therapy.
In this way, we succeeded in developing a highly reli-
able method for predicting responders to suplatast
therapy. In recent years, analysis of single-nucleotide
polymorphisms (SNPs) and gene expression analysis
in target tissues have often been used for predicting
the responses and adverse reactions to drugs. Based
on the results of the present study, we would like to
emphasize that routinely measured laboratory pa-
rameters can also sometimes serve as valid predic-
tors of responses to drug therapy.
METHODS
PATIENTS
Forty-four patients fulfilled the diagnostic criteria for
moderate to severe bronchial asthma described in
“ Guidelines for Prevention and Management of
Asthma”, revised edition published in 1998 (JGL’98),
Japan.10 Fourteen centers participated in the trial and
recruited asthma outpatients 20―64 years of age who
were taking 400―1600 μg of inhaled beclomethasone
dipropionate and less than 5 mg of oral prednisolone
daily for at least 8 weeks prior to the commencement
of the study. Other entry criteria included a forced
expiratory volume in 1 s (FEV1) of 50―80% of the pre-
dicted normal. Patients were excluded from the trial
if they had used Chinese herbal medicines, leukot-
riene receptor antagonists, 5-lipoxygenase inhibitors,
thromboxane synthase inhibitors, or thromboxane A2
antagonists during the 4 weeks prior to their pro-
posed entry into the study; or had received intramus-
cular or intravenous injections of corticosteroids or
bronchodilator during the 2-week run-in period; or
had been treated with allergen desensitization ther-
apy or non-specific therapy during that period. A his-
tory of serious disease or other drug-induced disor-
ders also precluded entry into the study. The protocol
(Fig . 1) for this study was approved by the multi-
center institutional review board , and written in-
formed consent was obtained from each of the partici-
pants prior to their entry into the study.
STUDY DESIGN
The phase II clinical trial of suplatast (300 and 600
mgday) in Japan11 was a multi-center , open-label ,
randomized, parallel-group controlled study involving
a 2-week run-in period (baseline) followed by an 8-
week treatment period. During the 2-week run-in pe-
riod, the patients continued to take their normal daily
dose of beclomethasone dipropionate from pressur-
ized metered-dose inhalers and received 3 capsules
daily of matching placebo. During the 8-week treat-
ment period, the patients were randomly assigned to
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Fig. 2 Changes from baseline in FEV1. FEV1 in the 300 
mg/day group increased significantly at week 6. (*P＜0.05 
by t test)
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Fig. 3 Changes from baseline in asthma symptom 
scores. Asthma symptom scores did not change from the 
baseline in either the 300 mg/day group or the 600 mg/day 
group.
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oral 300 mg suplatast (100 mg active capsule; 3 cap-
sules daily) or oral 600 mg suplatast (100 mg active
capsule; 6 capsules daily).
All the patients visited the outpatient clinic at least
once every 2 weeks throughout the study period. At
the baseline period, and at weeks 2, 4, 6, and 8 of
treatment, spirometry was performed. Each patient
was instructed to maintain a record in a booklet of all
the medications taken during the study period. The
asthma symptom scores were recorded along the
guidelines10 commonly used in Japan, 4 times daily
based on the severity of cough (severe, 1; mild, 0.5),
presence of chest tightness (1), presence of wheeze
(1), and the severity of asthma (mild, 3; moderate, 6;
severe, 9); and the total symptom scores for 2 weeks
were calculated. To assess safety, we did hematologi-
cal, biochemical, and urine analyses at the baseline
period, and at weeks 4 and 8 of treatment. Adverse
events were recorded daily and were reviewed by the
physician at every study-related visit to the study site.
An efficient response to suplatast was assessed first
at 4 weeks after the start of treatment. A response to
suplatast was judged as positive when an improve-
ment of greater than 10% occurred in the respiratory
function parameters (FEV1) , or when the asthma
symptom scores improved by an average of 1 point
day or 14 points in a 2 week period. (The maximum
possible symptom score of nonresponders and re-
sponders at baseline was 26.6 and 40.5, respectively).
STATISTICAL ANALYSIS
Primary endpoints were FEV1 and asthma symptom
scores. FEV1 was recorded every 2 weeks, and we
calculated the rate of change from the values at the
baseline. Asthma symptom scores recorded, 4 times
daily, were expressed as 2-week totals, and we deter-
mined the variation from the values at the baseline.
We used t tests to evaluate the significance of the dif-
ferences within and between groups , and P < 0.05
was taken to indicate significant differences.
A logistic regression analysis was also used to re-
late the response to the independent variables. The
independent variables considered in this study were
the clinical parameters used as outcome parameters
( respiratory function testing and asthma symptom
scores at the baseline period), pre-treatment labora-
tory test data (hematological, biochemical and urine
analyses ) , and the background variables ( body
weight, age of onset, severity, type of disease (atopic,
infectious and mixed ) , presence of complications ,
medical history , family history and treatment his-
tory). A univariate analysis was first performed to se-
lect the independent variables to predict the respond-
ers, with a P value of 0.05. A multivariate regression
model was then built using forward selection.
The software package SAS ver. 8.2 was used for the
statistical analyses.
VERIFYING THE PREDICTORS
The usefulness of the identified predictors was veri-
fied using the data from an independently performed
phase III clinical trial of suplatast (300 mgday) in Ja-
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Fig. 4 Changes from baseline in FEV1. FEV1 in the re-
sponder group increased significantly; whereas in the nonre-
sponder group there was no significant change from the 
baseline at weeks 4, 6, and 8, although the value decreased 
significantly at week 2. (*P＜0.05 by t test)
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Fig. 5 Changes from baseline in asthma symptom scores. 
Asthma symptom scores in the responder group decreased 
significantly at weeks 4 and 6; whereas in the nonresponder 
group they increased significantly at weeks 2, 4, and 6. (*P
＜0.05, **P＜0.01 by t test)
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Fig. 6 Percentage of blood eosinophils (%EOS) and blood basophils (%BASO) 
before the suplatast treatment. The responder group had a statisticaly lower 
%EOS and %BASO than the nonresponder group (P＝0.006 for %EOS and P＝
0.009 for %BASO according to the t test). The line across each diamond repre-
sents the group mean and the vertical span of each diamond represents the 95% 
confidence interval for each group.
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pan.12 Of the subjects of that study, 19 patients with
moderate to severe bronchial asthma on steroid ther-
apy who had undergone respiratory function testing
during the study were selected for this analysis. The
response of individual patients to suplatast was
judged using the same criteria as those employed in
the phase II study, except that the symptom scores
and respiratory function data in the 6th week were
substituted for the data in the 4th week of dosing, be-
cause these data in the 4th week were unavailable in
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p valueResponder (n＝22)Nonresponder (n＝22)
Age (yr)
0.53552.1 ± 13.349.6 ± 12.7Mean±SD
Gender
0.54010 8Female
1214Male
Dose
0.131 813300 mg/day
14 9600 mg/day
Asthma severity
0.1281510Moderate
 712Severe
Duration of asthma (yr)
0.26914.1 ± 9.8 18.4 ± 14.9Mean±SD
Serum IgE (IU/l)
0.256560.2 ± 759.3345.3 ± 435.6Mean＋SD
Beclomethasone use (μg/day)
0.140 8 3≦400―＜800
 510≦800―＜1200
 9 9＜1200―≦1600
FEV1
0.8031739.５ ± ５19.9 1774.7 ± 399.7 Mean ± SD
Symptom scores
0.06040.5 ± 25.726.6 ± 21.9Mean ± SD
P values for categorical data are obtained by χ2 test; P values for others are obtainde by t test.
Baseline characteristics of patients for nonresponder and responder groups. Distribution of age, gender, doses, asthma severity, asthma 
duration, serum IgE, beclomethasone, FEV1 and symptom scores did not difer significantly between the 2 groups. P values for categorical 
data are obtained by χ2 test and for others are obtained by t test.
Table 1 Measurements of run-in period
Table 2 Results of logistic regression
P Value
Upper
CL
Lower
CL
Odds
Ratio
Estimate
No. of
patients
VariableNo.
0.015*0.9660.7300.840－0.17444%blood eosinophils (%EOS)1
0.019*0.8110.0920.273－1.29744%blood basophils (%BASO)2
0.042*1.0221.0001.0110.01143Alkaline phosphatase3
0.06938.2170.8755.7831.75544Potassium4
0.0711.2240.9921.1020.09744Glutamic oxaloacetic transaminase5
0.1101.0680.9931.0300.02943γ-glutamyl transpeptidase6
0.11117.7020.7443.6291.28943Total protein7
0.1321.3280.1140.389－0.94444Severity8
0.1351.0070.9991.0030.00344Dose9
0.1521.1210.9821.0490.04844%blood lymphocytes10
P values are obtained by χ2 test. (*P＜0.05)
Results of univariate logistic regression. The top 10 variables with smalest P values are listed. P values are obtained by χ2 test. (*P＜
0.05)
the phase III study.
RESULTS
FEV1 increased significantly only at week 6 in the 300
mgday group (Fig. 2). Asthma symptom scores did
not change from the baseline in either the 300 mg
day group or the 600 mgday group (Fig. 3). There
were no significant differences between the 300 mg
day group and the 600 mgday group with respect to
FEV1 or asthma symptom scores.
In accordance with our criteria , we found 22 re-
sponders and 22 nonresponders to suplatast . Pa-
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Fig. 7 Changes in percentage of blood eosinophils (%EOS) and blood basophils 
(%BASO).
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tients’baseline characteristics are given in Table 1.
Distribution of age, gender, doses, asthma severity,
asthma duration , serum IgE , beclomethasone
dipropionate, FEV1 or symptom scores did not differ
significantly between the 2 groups. In the nonrespon-
der group the mean symptom score at baseline was
26.6 ± 21.9 and in the responder group it was 40.5 ±
25.7. FEV1 in the responder group increased signifi-
cantly; whereas in the nonresponder group there was
no significant change from the baseline at weeks 4, 6,
and 8, although the value decreased significantly at
week 2 (Fig. 4). There were significant differences
between the 2 groups at all time points . Asthma
symptom scores in the responder group decreased
significantly at weeks 4 and 6, and in the nonrespon-
der group increased significantly at weeks 2, 4 and 6
(Fig. 5). There were significant differences between
the 2 groups at all time points except week 8.
Obtained by use of univariate logistic regression,
the top 10 variables with smallest P values are listed
in Table 2. In the univariate regression, the independ-
ent variables %EOS (P = 0.015), %BASO (P = 0.019)
and alkaline phosphatase (P = 0.042) were found to
be significantly related to the response to suplatast.
Among these, %EOS and %BASO remained in the
multivariate regression model. In fact, the absolute %
EOS (P = 0.006) and %BASO (P = 0.009) before the
suplatast treatment were significantly lower in the re-
sponder group than in the nonresponder group (Fig.
6). On the other hand, %EOS and %BASO did not
reach statistically significant levels from the baseline
in either the responder group or the nonresponder
group (Fig. 7).
We then evaluated the accuracy of prediction of the
response to suplatast on the basis of the %EOS and
%BASO when the cut-off levels were set at 7.5 and 1.2,
respectively (Table 3). When we used the combina-
tion of %EOS and %BASO , the positive predictive
value was calculated to be 81.8% (18 out of 22 cases),
whereas the percentage of responders in the entire
population was 50.0% (Fig. 8). To verify the validity of
this method of prediction, we applied the same cut-off
levels to the data obtained during a phase III clinical
trial of suplatast (Fig. 9). When the analysis was con-
ducted using these cut-off levels in 19 cases of moder-
ate to severe bronchial asthma on steroid therapy,
the sensitivity of this method of prediction was found
to be as high as 75.0%, whereas the percentage of re-
sponders in the total population was 52.6%.
DISCUSSION
Before a drug is prescribed to a given patient , at-
tempts to predict the response and adverse reactions
of the patients to the drug have, in recent times, often
been made by means of SNP analysis, gene expres-
sion analysis, or proteome analysis of target tissues.
In the present study, we sought to identify the factors
potentially contributing to the response of individual
patients to the drug therapy among routinely meas-
ured laboratory parameters and patient background
variables.
In the Phase II study we could not show any dose-
response effect of suplatast. However, it should be
noted that the study group comprised both patients
with and those without a positive response to
suplatast . To assess the response to suplatast , we
used FEV1 and asthma symptom scores obtained first
at 4 weeks after the start of treatment. Using our cri-
teria , in the responder group , FEV1 was also im-
proved significantly at weeks 6 and 8, and asthma
symptom scores were improved significantly at week
6. These results indicate that the criteria could dis-
criminate responders and nonresponders success-
fully.
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Table 3 Summary of response data
P value
Ratio of
responder (%)
No. of
responder
No. of
Nonresponder
No. of
patients
%EOS and %BASO levels
0.00467.919 928%EOS＜7.5
18.8 31316%EOS≧7.5
0.00366.7201030%BASO＜1.2
14.3 21214%BASO≧1.2
＜0.00181.818 422%EOS＜7.5 and %BASO＜1.2
18.2 41822%EOS≧7.5 or %BASO≧1.2
P values are obtained by Fisher’ sexact test.
Summary of response data for suplatast with diferent levels of %EOS and %BASO. P values are obtained by Fisher’ sexact test.
We also used logistic regression to study the fac-
tors predicting an efficient response to suplatast. In
this analysis %EOS and %BASO were selected as pre-
dictors. When the response to drug therapy was pre-
dicted on the basis of the predictors thus identified
(%EOS and %BASO), the positive predictive value was
as high as 81.8% . This method of prediction was
found to be satisfactorily valid when it was verified by
applying the same predictors to the data from an in-
dependently performed phase III clinical trial. These
results suggest that the combination of %EOS and
%BASO might be a predictive marker for responders
to suplatast , although the mechanism has not yet
been fully elucidated.
Our results suggest that asthma patients on steroid
therapy who have a low %EOS and %BASO prior to
the start of treatment are more likely to respond to
suplatast over the relatively short term (4 weeks) .
Furthermore, in the responder group %EOS and %
BASO were stable at a lower level during the treat-
ment periods, whereas in the nonresponder group
they fluctuated greatly (Fig. 7). The mechanism by
which the pre-treatment %EOS and %BASO influence
the response of asthma patients on inhaled steroid
therapy to suplatast remains to be clarified. In the pa-
tients with low %EOS and %BASO not receiving in-
haled steroids, the response rate to suplatast was not
so high among asthmatic patients during the phase
III clinical trial of suplatast (data not shown). This
finding suggests that the effectiveness of suplatast
may be related to the mechanism by which steroids
exert their anti-allergy activity.
It was previously reported that treatment with
suplatast reduced the elevated blood eosinophil count
in patients13-16 or the number of eosinophils infiltrat-
ing the inflamed tissues.9,17 Also in the present phase
II clinical trial, some of the patients with elevated %
EOS who were on steroid therapy showed a decrease
in their %EOS following 4 weeks of suplatast therapy.
Therefore, we could speculate that suplatast provides
better improvement in the patients with increased
eosinophils. However, our study indicated exactly the
contrary results, suggesting that the responders of
suplatast might be the patients who had markedly re-
duced eosinophils with steroid therapy. These find-
ings suggest the necessity of following up and analyz-
ing the course of asthma patients with elevated %EOS
for long periods of time. It would seem essential to
examine whether or not prolonged suplatast therapy
may be useful over the long term in asthma patients
on inhaled steroid therapy who showed a decrease in
the %EOS during short-term suplatast therapy, even if
the asthma symptoms showed no improvement dur-
ing this period. It would be desirable for large scale
prospective studies to be performed in the near fu-
ture to resolve these issues.
Recently , analyses of SNPs , 18,19 gene expres-
sion, 20,21 proteomes , 22,23 and metabonome 24 have
been conducted in the hope of obtaining an important
base for tailored medicine.25 The results of the pre-
sent study serve to emphasize that factors determin-
ing the sensitivity to a drug may even be identified by
relatively simple analysis of the laboratory data and
background variables of the patients . When com-
bined with genomic information, these data may con-
tribute to stratified medical treatment in the future
that can be tailored to individual patients.
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Fig. 8 Percentage of blood eosinophils (%EOS) ploted 
against blood basophils (%BASO) in the same set of 44 pa-
tients in a phase I clinical trial. Solid and empty circles indi-
cate responders and nonresponders, respectively. The 
doted lines indicate the response cut-of values (%EOS＝
7.5 and %BASO＝1.2). The response rate was 81.8% (18 
of 22) in patients with low %EOS and %BASO.
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Fig. 9 The same cut-of levels were applied to 19 patients 
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sponders and nonresponders, respectively. The doted lines 
indicate the response cut-of values (%EOS＝ 7.5 and 
%BASO＝1.2). The response rate was 75.0% (6 of 8) in pa-
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